Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels a cohort study

Annals of Internal Medicine

Volumn 155, Issue 11, 2011, Pages 742-750

  Mora, Samia ^a   Buring, Julie E ^a   Ridker, Paul M ^a   Cui, Yadong ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FEMALE; HEALTH CARE PERSONNEL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMMUNOASSAY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS; STROKE;

EID: 82855167195     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-155-11-201112060-00006     Document Type: Article

References (26)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421. [PMID: 12485966]
2. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Intern Med. 2006;259:493-519. [PMID: 16629855]
3. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-14. [PMID: 193398]
4. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study. Can J Cardiol. 1988;4 Suppl A:5A-10A. [PMID: 3179802]
5. Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res. 1994;35:779-92.[PMID: 8071601]
6. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124 Suppl:S11-20. [PMID: 8831911]
7. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108-13. [PMID: 11535564]
8. Luc G, Bard JM, Ferriêres J, Evans A, Amouyel P, Arveiler D, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2002;22: 1155-61. [PMID: 12117731]
9. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al; Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000. [PMID: 19903920]
10. deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of highdensity lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2008;51:49-55. [PMID: 18174036]
11. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993;153:2209-16. [PMID: 8215724]
12. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:47-55. [PMID: 15998890]
13. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:56-65. [PMID: 15998891]
14. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304. [PMID: 15753114]
15. Hainline A, Karon J, Lippel K. Manual of Laboratory Operations: Lipid Research Clinics Program and Lipid and Lipoprotein Analysis. Bethesda, MD: U.S. Department of Health and Human Services; 1982:628.
16. Rosenbaum PR. Discussing hidden bias in observational studies. Ann Intern Med. 1991;115:901-5. [PMID: 1952480]
17. Bittner V. Perspectives on dyslipidemia and coronary heart disease in women. J Am Coll Cardiol. 2005;46:1628-35. [PMID: 16256860]
18. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112:3375-83. [PMID: 16316964]
19. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006;259:247-58. [PMID: 16476102]
20. Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literaturebased meta-analysis of prospective studies. J Intern Med. 2006;259:481-92. [PMID: 16629854]
21. Sniderman AD. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is [Editorial]. Circulation. 2005;112:3366-7. [PMID: 16316960]
22. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;51:634-42. [PMID: 18261682]
23. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298:786-98. [PMID: 17699012]
24. Warner JG Jr, Brubaker PH, Zhu Y, Morgan TM, Ribisl PM, Miller HS, et al. Long-term (5-year) changes in HDL cholesterol in cardiac rehabilitation patients. Do sex differences exist? Circulation. 1995;92:773-7. [PMID: 7641355]
25. Haffner SM; American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27 Suppl 1:S68-71. [PMID: 14693930]
26. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al; American Heart Association. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52. [PMID: 16157765]